OpenAI launches Rosalind Academic Plan offering free GPT-Rosalind access to eligible labs

OpenAI has introduced the Rosalind Academic Plan, providing sponsored access to GPT-Rosalind, a dedicated life sciences model, for eligible academic research labs. The plan aims to support foundational scientific discovery by combining frontier reasoning with the Rosalind Workbench, which enables specialized tool orchestration across medicinal chemistry, genomics, and wet-lab assistance.

Plan Details and Eligibility

Eligible labs at U.S. universities can receive up to 30 Business Standard seats at $0 per user per month for up to 12 months. Access to GPT-Rosalind is subject to trusted-access approval, which involves verifying the institution’s legitimacy, the Principal Investigator’s (PI) identity, and the lab’s research activities. Labs at universities with an existing OpenAI Enterprise agreement must apply through their university’s Enterprise access process, while others apply directly.

Features and Restrictions

The plan includes access to all commercially available frontier OpenAI models, subject to usage limits, alongside GPT-Rosalind. Key features include:

• Data Privacy: Research data shared through the plan is not used to train OpenAI models by default.
• API Access: API access is not included at this time.
• Management: Verified PIs and lab leads manage member permissions and are responsible for approved use.

Safety and Use Cases

GPT-Rosalind is designed for complex biological questions, including drug and protein design, with safeguards for sensitive scientific inquiries. The article contrasts GPT-Rosalind’s detailed, actionable responses for legitimate research (such as designing antiviral therapeutics) with the more restrictive, high-level guidance provided by the standard Mainline Astra model for similar requests involving high-consequence pathogens. Current users include labs at UCSF, Stanford University, and the Arc Institute, applying the model to tasks like quantitative drug development and understanding neurodegeneration.